000998 隆平高科
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,581,899-1.28%9,223,2177,532,0713,503,4423,290,528
减:营业总成本3,251,49216.02%8,569,1027,301,8913,410,6853,029,154
    其中:营业成本1,762,4586.21%5,555,7204,607,5882,302,7582,020,756
               财务费用440,898167.46%397,896476,443100,34174,689
               资产减值损失(53,826)4.14%(243,571)(451,484)(450,213)(32,399)
公允价值变动收益7,012-107.98%(103,153)(16,437)11,338(124,327)
投资收益347,261-1,230.61%(39,125)(21,233)583,300125,845
    其中:对联营企业和合营企业的投资收益(2,813)-91.85%(52,442)(90,283)118,784115,793
营业利润(289,106)-10.49%362,550(270,011)215,761273,292
利润总额(292,461)-9.98%361,510(295,037)190,854250,060
减:所得税费用(206,113)100.66%(12,038)137,33917,67417,672
净利润(86,347)-61.14%373,549(432,376)173,180232,388
减:非控股权益(197,636)222.27%173,494400,493110,733116,485
股东净利润111,289-169.19%200,055(832,869)62,447115,903

市场价值指针
每股收益 (元) *0.085-169.21%0.150-0.6400.0500.090
每股派息 (元) *----0.050------
每股净资产 (元) *3.869-2.56%4.2573.8254.1814.184
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容